Table 3.
Characteristics of patients grouped by timing of relapse*
| Variable | Relapse <24 months | Relapse after 24 months | No Relapse |
|---|---|---|---|
| Number of patients | 1156 | 984 | 893 |
| Age at transplant, years | |||
| median age (range) | 58 (31–80) | 60 (28–78) | 59 (22–80) |
| <50 | 216 (19) | 171 (18) | 167 (19) |
| 50–69 | 857 (75) | 747 (76) | 676 (76) |
| 70+ | 83 (7) | 66 (7) | 50 (6) |
| Gender | |||
| Male | 697 (60) | 596 (61) | 512 (57) |
| Karnofsky Performance Score | |||
| ≥ 90% | 623 (54) | 535 (54) | 506 (57) |
| < 90% | 436 (38) | 369 (38) | 331 (37) |
| Unknown | 97 (8) | 80 (8) | 56 (6) |
| Disease-related variables | |||
| Immunochemical subtype | |||
| IgG | 619 (54) | 565 (57) | 519 (58) |
| IgA | 300 (26) | 209 (21) | 152 (17) |
| Light chain | 186 (16) | 169 (17) | 191 (21) |
| Others | 17 (1) | 12 (1) | 9 (1) |
| Non-secretory | 31 (3) | 27 (3) | 20 (2) |
| Serum Creatinine at diagnosis | |||
| < 2 mg/dl | 787 (68) | 666 (68) | 597 (67) |
| ≥ 2 mg/dl | 196 (17) | 152 (15) | 131 (15) |
| Unknown | 173 (15) | 166 (17) | 165 (18) |
| Serum Albumin at diagnosis | |||
| < 3.5 g/dl | 384 (33) | 306 (31) | 254 (28) |
| ≥ 3.5 g/dl | 515 (45) | 473 (48) | 448 (50) |
| Unknown | 257 (22) | 205 (21) | 191 (21) |
| ISS/DS Stage III | |||
| Yes | 474 (41) | 367 (37) | 300 (34) |
| No | 629 (54) | 580 (59) | 554 (62) |
| Missing | 53 (5) | 37 (4) | 39 (4) |
| Transplant-related variables | |||
| Lines of chemotherapy | |||
| 1 | 783 (68) | 701 (71) | 683 (76) |
| 2 | 302 (26) | 223 (23) | 167 (19) |
| 3+ | 71 (6) | 60 (6) | 43 (5) |
| Chemotherapy | |||
| VTD | 98 (8) | 93 (9) | 64 (7) |
| RVD | 181 (16) | 94 (10) | 211 (24) |
| CVD | 80 (7) | 63 (6) | 72 (8) |
| VD | 76 (7) | 55 (6) | 79 (9) |
| RD | 134 (12) | 88 (9) | 103 (12) |
| TD | 234 (20) | 276 (28) | 152 (17) |
| VAD/similar | 353 (31) | 315 (32) | 212 (24) |
| Melphalan dose (mg/m2) for condition regimen | |||
| 140 | 198 (17) | 146 (15) | 128 (14) |
| 200 | 958 (83) | 838 (85) | 765 (86) |
| Total No. of CD34 cells infused (×106/kg) | |||
| Median (range) | 4.81 (1.00–19.11) | 5.34 (1.18–19.70) | 5.08 (1.19–19.56) |
| Disease status at transplant | |||
| CR | 142 (12) | 140 (14) | 171 (19) |
| PR | 860 (74) | 760 (77) | 652 (73) |
| MR/NR/SD | 108 (9) | 67 (7) | 56 (6) |
| Relapse/Progression | 45 (4) | 16 (2) | 14 (2) |
| Unknown | 1 (<1) | 1 (<1) | 0 |
| Sensitivity to chemotherapy | |||
| Sensitive | 1002 (87) | 900 (91) | 823 (92) |
| Resistant | 153 (13) | 83 (8) | 70 (8) |
| Unknown | 1 (<1) | 1 (<1) | 0 |
| Time from diagnosis to transplant | |||
| < 6 months | 368 (32) | 325 (33) | 301 (34) |
| 6 – 12 months | 788 (68) | 659 (67) | 592 (66) |
| Year of transplant | |||
| 2001–2004 | 331 (29) | 325 (33) | 198 (22) |
| 2005–2008 | 520 (45) | 503 (51) | 323 (36) |
| 2009–2013 | 305 (26) | 156 (16) | 372 (42) |
| Median follow-up of survivors (range), months | 75 (24–169) | 97 (25–170) | 60 (24–170) |
| Post-transplant characteristics | |||
| Post-relapse salvage transplant | |||
| No salvage transplant | 938 (81) | 699 (71) | 893 |
| Salvage AutoHCT | 159 (14) | 267 (27) | 0 |
| Salvage AlloHCT | 59 (5) | 18 (2) | 0 |
| Time from transplant to relapse | |||
| < 12 months | 624 (54) | 0 | |
| 12 – 24 months | 532 (46) | 0 | |
| 24 – 36 months | 0 | 392 (40) | |
| > 36 months | 0 | 236 (24) | |
| Planned post-HCT therapy | |||
| Novel agents (Lena+Bort/Lena/Bort) | 272 (24) | 254 (26) | 370 (41) |
| Other agents | 20 (2) | 39 (4) | 28 (3) |
| None | 813 (70) | 644 (65) | 485 (54) |
| Missing | 51 (4) | 47 (5) | 10 (1) |
*
Limited to patients with at least 24 months follow up if still alive
Legend VTD, boretezomib, thalidomide and dexamethasone; RVD, lenalidomide, bortezomib and dexamethasone; CVD, cyclophosphamide, bortezomib and dexamethasone; VD, bortezomib, dexamethasone; RD, lenalidomide, dexamethasone; TD, thalidomide, dexamethasone; VAD, vincristine, doxorubicin, and dexamethasone; CR, complete response; VGPR, very good partial response; PR, partial response; MR, minor response; NR, no response; SD, stable disease; HCT hematopoietic cell transplantation